fda ban compounded tirzepatide New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Proposes Ban on Bulk

Please consult your doctor for guidance on the medications that may be appropriate for you

Sample Email Pitch to a Social Media Influencer Subject: Collaborate with Us: Exciting Opportunity for [Influencer Name] to Join Our Medical Weight Loss Launch

Intracerebral haemorrhage expansion: definitions, predictors, and prevention

I do think red light works and its another tool in your tool belt, adds Dr

The Medicare GLP-1 Bridge is a temporary nationwide program that lets eligible people with Medicare prescription drug coverage buy certain GLP-1 weight-loss medications for a flat $50 monthly copay, no matter what their income level is

Our formulation strategy is designed to preserve the tripeptide's bioactivity from the manufacturing vessel to the consumer's skin